NeuTrace
Analysis completed on 3/17/2026
NeuTrace (acquired by Anumana) demonstrates strong technical innovation and real-world utility in Cardiac Electrophysiology. However, the submission itself is highly questionable, containing exaggerated and unsupported claims ('everyone', 'most people have used my product') alongside a nonsensical revenue metric. This leads to heavily penalized quality factors for reach, traction, and response quality.
Ready to Compete for $150k+ in Prizes?
Move this data into a HackerNoon blog draft to become eligible for your share of $150k+ in cash and software prizes
Score Breakdown
Project Details
Algorithm Insights
Recommendations to Increase Usefulness Score
Document User Growth
Provide specific metrics on user acquisition and retention rates
Showcase Revenue Model
Detail sustainable monetization strategy and current revenue streams
Expand Evidence Base
Include testimonials, case studies, and third-party validation
Technical Roadmap
Share development milestones and feature completion timeline